DK3082860T3 - Fremgangsmåde til behandling af sår - Google Patents

Fremgangsmåde til behandling af sår Download PDF

Info

Publication number
DK3082860T3
DK3082860T3 DK14871427.2T DK14871427T DK3082860T3 DK 3082860 T3 DK3082860 T3 DK 3082860T3 DK 14871427 T DK14871427 T DK 14871427T DK 3082860 T3 DK3082860 T3 DK 3082860T3
Authority
DK
Denmark
Prior art keywords
procedure
wound treatment
wound
treatment
Prior art date
Application number
DK14871427.2T
Other languages
English (en)
Inventor
Ulf Eriksson
Annelie Falkevall
Annika Mehlem
Original Assignee
Csl Ltd
B Creative Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904942A external-priority patent/AU2013904942A0/en
Application filed by Csl Ltd, B Creative Sweden Ab filed Critical Csl Ltd
Application granted granted Critical
Publication of DK3082860T3 publication Critical patent/DK3082860T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14871427.2T 2013-12-18 2014-12-18 Fremgangsmåde til behandling af sår DK3082860T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013904942A AU2013904942A0 (en) 2013-12-18 Method of treating wounds
AU2013904966A AU2013904966A0 (en) 2013-12-19 Method of treating wounds
PCT/AU2014/050431 WO2015089585A1 (en) 2013-12-18 2014-12-18 Method of treating wounds

Publications (1)

Publication Number Publication Date
DK3082860T3 true DK3082860T3 (da) 2021-01-25

Family

ID=53401804

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14871427.2T DK3082860T3 (da) 2013-12-18 2014-12-18 Fremgangsmåde til behandling af sår

Country Status (13)

Country Link
US (1) US10543270B2 (da)
EP (1) EP3082860B1 (da)
JP (1) JP6553618B2 (da)
KR (2) KR20160096194A (da)
CN (1) CN105979965B (da)
AU (1) AU2014366837B2 (da)
BR (1) BR112016014099A2 (da)
CA (1) CA2932465C (da)
DK (1) DK3082860T3 (da)
ES (1) ES2851386T3 (da)
PL (1) PL3082860T3 (da)
RU (1) RU2672377C1 (da)
WO (1) WO2015089585A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102560025B1 (ko) 2014-11-17 2023-07-26 씨에스엘 리미티드 뇌졸중의 치료 또는 예방 방법
BR112018071467A2 (pt) 2016-04-21 2019-02-05 B Creative Sweden Ab método de tratamento ou prevenção de patologias hepáticas
WO2023115112A1 (en) * 2021-12-20 2023-06-29 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DE69334258D1 (de) 1992-08-21 2009-02-26 Univ Bruxelles Immunoglobuline ohne Leichtkette
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
CA2145278C (en) 1992-09-25 2009-03-10 Peter J. Hudson Target binding polypeptide
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
NZ507093A (en) 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
DE60236861D1 (de) 2001-04-26 2010-08-12 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
DE60310383T2 (de) * 2002-01-29 2007-09-20 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Vorbeugung von gewebeadhäsion
US20040005671A1 (en) * 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN1822857A (zh) 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
ATE416190T1 (de) 2003-07-04 2008-12-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
AU2005250055B2 (en) 2004-06-02 2008-09-11 Adalta Pty Ltd Binding moieties based on shark IgNAR domains
DK1781321T3 (da) * 2004-08-02 2014-04-14 Zenyth Operations Pty Ltd Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2619244A1 (en) 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
NZ579107A (en) * 2007-02-19 2012-05-25 Marinepolymer Tech Inc Poly-beta-1-4-n-acetylglucosamine hemostatic compositions and therapeutic regimens
US20100216865A1 (en) 2007-09-12 2010-08-26 Elias Jack A MicroRNA COMPOSITIONS IN THE TREATMENT OF VEGF-MEDIATED DISORDERS
US20110150900A1 (en) * 2008-04-09 2011-06-23 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
AU2009269149B2 (en) * 2008-06-30 2016-03-17 Mesoblast, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
RU2395521C1 (ru) * 2008-11-10 2010-07-27 Учреждение Российской Академии Наук Институт Биологии Гена Ран Наноантитело v9, связывающее vegf, и способ его получения, кодирующая v9 нуклеотидная последовательность и содержащий ее вектор, способ ингибирования пролиферации эндотелиальных клеток
MX348166B (es) 2008-12-19 2017-06-01 Macrogenics Inc Diacuerpos covalentes y sus usos.
US9259507B2 (en) * 2009-04-21 2016-02-16 Warsaw Orthopedic, Inc. Tissue augmentation with active agent for wound healing
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires

Also Published As

Publication number Publication date
KR20160096194A (ko) 2016-08-12
KR20220115815A (ko) 2022-08-18
CN105979965A (zh) 2016-09-28
JP6553618B2 (ja) 2019-07-31
EP3082860A4 (en) 2017-08-16
EP3082860B1 (en) 2020-11-25
RU2672377C1 (ru) 2018-11-14
BR112016014099A2 (pt) 2017-10-10
EP3082860A1 (en) 2016-10-26
PL3082860T3 (pl) 2021-06-14
WO2015089585A1 (en) 2015-06-25
US20160319008A1 (en) 2016-11-03
ES2851386T3 (es) 2021-09-06
KR102466794B1 (ko) 2022-11-11
JP2017501182A (ja) 2017-01-12
CA2932465A1 (en) 2015-06-25
CN105979965B (zh) 2021-07-09
AU2014366837A1 (en) 2016-06-16
CA2932465C (en) 2023-08-22
AU2014366837B2 (en) 2020-06-25
RU2016127196A (ru) 2018-01-23
US10543270B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
DK3220863T3 (da) Sårforbindinger
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2968208T3 (da) Behandling af kataplexi
DK3545906T3 (da) Indretning til udskiftning af hjerteklap
DK2996556T3 (da) System til billedstyret procedure
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK3027615T3 (da) Antiinfektionsforbindelser
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3007726T3 (da) Fremgangsmåder til behandling af en tauopati
DK3016493T3 (da) Behandling til desinficering af frø
DK3076786T3 (da) Fælde
DK2992104T3 (da) Fremgangsmåde til ekspression
BR112015021083A2 (pt) método
DK2956698T3 (da) Bindestrimler
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3369724T3 (da) Fremgangsmåde til fremstilling af iopamidol
DK2946640T3 (da) Langmuir-probe
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose
BR112015029076A2 (pt) método
DK3068314T3 (da) Årepresse
DK2986325T3 (da) Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus
DK2964248T3 (da) Behandling af og profylakse for stråledermatitis